您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > (E,E)-Bisdemethoxycurcumin
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
(E,E)-Bisdemethoxycurcumin
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
(E,E)-Bisdemethoxycurcumin图片
CAS NO:33171-05-0
包装与价格:
包装价格(元)
10 mM * 1 mL in DMSO电议
5mg电议
10mg电议
50mg电议
100mg电议
200mg电议
500mg电议

产品名称
双去甲氧基姜黄素
(E,E)-Curcumin III
(E,E)-Didemethoxycurcumin
产品介绍
(E,E)-Bisdemethoxycurcumin ((E,E)-Curcumin III) 是姜黄素衍生物,具有抗炎症和抗癌活性。
生物活性

Bisdemethoxycurcumin(Curcumin III; Didemethoxycurcumin) is a natural derivative of curcumin with anti-inflammatory and anti-cancer activities. IC50 value: Target: Anticancer natural compound in vitro: BDMC-inducedapoptosiswas mediated by a combinatory inhibition of cytoprotective proteins, such as Bcl2 and heme oxygenase-1 and increased generation ofreactive oxygen species. Intriguingly, BDMC-inducedapoptosiswas reversed with co-treatment of sr144528, acannabinoid receptor(CBR) 2 antagonist, which was confirmed with genetic downregulation of the receptor using siCBR2 [1]. Induction of cell cycle arrest in HepG2 cells by NB and BDCur in combination was evidenced by accumulation of the G2/M cell population. Further investigation on the molecular mechanism showed that NB and BDCur in combination resulted in a significant decrease in the expression level of Cdc2 and cyclin B [2]. BDMC treatment activated Sirt1/AMPK signaling pathway. Moreover, downregulatingSirt1by the pharmacological inhibitor nicotianamine orsmall interfering RNAblocked BDMC-mediated protection against t-BHP-mediated decrease in proliferation [4]. in vivo: human gastric adenocarcinoma xenograft model was generated in vivo using nude mice and BDMC was observed to suppress the growth and activity of tumors, in addition to improving the physical and mental capacity of the mice [3].

分子量

308.33

性状

Solid

Formula

C19H16O4

CAS 号

33171-05-0

中文名称

双去甲氧基姜黄素

结构分类
  • Phenols
  • Polyphenols
来源
  • Plants
  • Zingiberaceae
  • Zingiber officinale
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder-20°C3 years
4°C2 years
In solvent-80°C6 months
-20°C1 month
溶解性数据
In Vitro: 

DMSO : ≥ 100 mg/mL(324.33 mM)

*"≥" means soluble, but saturation unknown.

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM3.2433 mL16.2164 mL32.4328 mL
5 mM0.6487 mL3.2433 mL6.4866 mL
10 mM0.3243 mL1.6216 mL3.2433 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40%PEG300   5%Tween-80   45% saline

    Solubility: ≥ 2.5 mg/mL (8.11 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (8.11 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH2O 中,得到澄清透明的生理盐水溶液
*以上所有助溶剂都可在本网站选购。